CYP2D6 genotypes in cigarette smokers and non-tobacco users

被引：32

作者：

Cholerton, S ^{[1
]}

Boustead, C ^{[1
]}

Taber, H ^{[1
]}

Arpanahi, A ^{[1
]}

Idle, JR ^{[1
]}

机构：

[1] NORWEGIAN UNIV SCI & TECHNOL,INST CANC RES & MOL BIOL,N-7005 TRONDHEIM,NORWAY

来源：

PHARMACOGENETICS | 1996年 / 6卷 / 03期

关键词：

CYP2D6; genotype; cigarette smoking;

D O I：

10.1097/00008571-199606000-00010

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：261 / 263

页数：3

共 11 条

[1] METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER [J].

AYESH, R ;

IDLE, JR ;

RITCHIE, JC ;

CROTHERS, MJ ;

HETZEL, MR .

NATURE, 1984, 312 (5990) :169-170

[2] LUNG-CANCER AND THE DEBRISOQUINE METABOLIC PHENOTYPE [J].

CAPORASO, NE ;

TUCKER, MA ;

HOOVER, RN ;

HAYES, RB ;

PICKLE, LW ;

ISSAQ, HJ ;

MUSCHIK, GM ;

GREENGALLO, L ;

BUIVYS, D ;

AISNER, S ;

RESAU, JH ;

TRUMP, BF ;

TOLLERUD, D ;

WESTON, A ;

HARRIS, CC .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (15) :1264-1272

[3] THE ROLE OF INDIVIDUAL HUMAN CYTOCHROMES-P450 IN DRUG-METABOLISM AND CLINICAL-RESPONSE [J].

CHOLERTON, S ;

DALY, AK ;

IDLE, JR .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (12) :434-439

[4] GENETIC AND METABOLIC CRITERIA FOR THE ASSIGNMENT OF DEBRISOQUINE 4-HYDROXYLATION (CYTOCHROME-P4502D6) PHENOTYPES [J].

DALY, AK ;

ARMSTRONG, M ;

MONKMAN, SC ;

IDLE, ME ;

IDLE, JR .

PHARMACOGENETICS, 1991, 1 (01) :33-41

[5] THE PHARMACOGENETICS OF CHEMICAL CARCINOGENESIS [J].

IDLE, JR ;

ARMSTRONG, M ;

BODDY, AV ;

BOUSTEAD, C ;

CHOLERTON, S ;

COOPER, J ;

DALY, AK ;

ELLIS, J ;

GREGORY, W ;

HADIDI, H ;

HOFER, C ;

HOLT, J ;

LEATHART, J ;

MCCRACKEN, N ;

MONKMAN, SC ;

PAINTER, JE ;

TABER, H ;

WALKER, D ;

YULE, M .

PHARMACOGENETICS, 1992, 2 (06) :246-258

[6] METHODOLOGICAL ISSUES IN THE INTERPRETATION OF STUDIES OF THE CYP2D6 GENOTYPE IN RELATION TO LUNG-CANCER RISK [J].

LONDON, SJ ;

DALY, AK ;

THOMAS, DC ;

CAPORASO, NE ;

IDLE, JR .

PHARMACOGENETICS, 1994, 4 (02) :107-108

[7]

OATES NS, 1987, P 10 INT C PHARM, pP91

[8]

TEFRE T, 1994, PHARMACOGENETICS, V4, P47

[9]

TURGEON J, 1995, CLIN PHARMACOL THER, V57, P150

[10] CYP2D6 GENOTYPING AND THE ASSOCIATION WITH LUNG-CANCER SUSCEPTIBILITY [J].

WOLF, CR ;

SMITH, CAD ;

BISHOP, T ;

FORMAN, D ;

GOUGH, AC ;

SPURR, NK .

PHARMACOGENETICS, 1994, 4 (02) :104-106

← 1 2 →